Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | OGFRL1 | Q5TC84 | 5/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL51875 | 1.00 | CHRNB2 (0.34) | CHRNB2CHRNB4CHRNA3CHRNA4OGFRL1 | |
| SCHEMBL51652 | 0.85 | OGFRL1 (0.33) | CHRNB2CHRNB4CHRNA3CHRNA4OGFRL1 | |
| SCHEMBL51876 | 0.81 | — | — | |
| SCHEMBL61820 | 0.78 | OGFRL1 (0.37) | CHRNB2CHRNB4CHRNA3CHRNA4OGFRL1 | |
| SCHEMBL62910 | 0.78 | OGFRL1 (0.35) | CHRNB2CHRNB4CHRNA3CHRNA4OGFRL1 | |
| SCHEMBL51828 | 0.77 | SMN1; SMN2 (0.37) | OGFRL1OPRM1OPRK1OPRD1KDM4E | |
| SCHEMBL51443 | 0.76 | CHRNB2 (0.47) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL62529 | 0.73 | ERCC1 (0.35) | KDM4EMAPT | |
| SCHEMBL51795 | 0.73 | ERCC1 (0.35) | KDM4EMAPT | |
| SCHEMBL51796 | 0.73 | ERCC1 (0.35) | KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253677-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | CHRNB2 4393/4885CHRNB4 4428/4885CHRNA3 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.